94 related articles for article (PubMed ID: 9413270)
1. Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound.
Patrini G; Sacerdote P; Fuzio D; Manfredi B; Parolaro D
J Neuroimmunol; 1997 Dec; 80(1-2):143-8. PubMed ID: 9413270
[TBL] [Abstract][Full Text] [Related]
2. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940.
Rubino T; Viganò D; Massi P; Parolaro D
J Neurochem; 2000 Nov; 75(5):2080-6. PubMed ID: 11032897
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors.
Sacerdote P; Massi P; Panerai AE; Parolaro D
J Neuroimmunol; 2000 Sep; 109(2):155-63. PubMed ID: 10996217
[TBL] [Abstract][Full Text] [Related]
4. Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus.
Miller AS; Sañudo-Peña MC; Walker JM
Brain Res; 1998 May; 793(1-2):7-11. PubMed ID: 9630477
[TBL] [Abstract][Full Text] [Related]
5. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.
Rinaldi-Carmona M; Barth F; Millan J; Derocq JM; Casellas P; Congy C; Oustric D; Sarran M; Bouaboula M; Calandra B; Portier M; Shire D; Brelière JC; Le Fur GL
J Pharmacol Exp Ther; 1998 Feb; 284(2):644-50. PubMed ID: 9454810
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.
Lay L; Angus JA; Wright CE
Eur J Pharmacol; 2000 Mar; 391(1-2):151-61. PubMed ID: 10720647
[TBL] [Abstract][Full Text] [Related]
7. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat.
Chapman V
Br J Pharmacol; 1999 Aug; 127(8):1765-7. PubMed ID: 10482905
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoids and opioids share cAMP pathway in rat splenocytes.
Massi P; Vaccani A; Rubino T; Parolaro D
J Neuroimmunol; 2003 Dec; 145(1-2):46-54. PubMed ID: 14644030
[TBL] [Abstract][Full Text] [Related]
9. Changes in rat spleen cannabinoid receptors after chronic CP-55,940: an autoradiographic study.
Massi P; Patrini G; Rubino T; Fuzio D; Parolaro D
Pharmacol Biochem Behav; 1997 Sep; 58(1):73-8. PubMed ID: 9264073
[TBL] [Abstract][Full Text] [Related]
10. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats.
Wiley JL; Barrett RL; Lowe J; Balster RL; Martin BR
Neuropharmacology; 1995 Jun; 34(6):669-76. PubMed ID: 7566504
[TBL] [Abstract][Full Text] [Related]
11. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
12. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects.
Massi P; Vaccani A; Romorini S; Parolaro D
J Neuroimmunol; 2001 Jul; 117(1-2):116-24. PubMed ID: 11431011
[TBL] [Abstract][Full Text] [Related]
13. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity.
Massi P; Fuzio D; Viganò D; Sacerdote P; Parolaro D
Eur J Pharmacol; 2000 Jan; 387(3):343-7. PubMed ID: 10650181
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
16. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
17. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats.
Mansbach RS; Rovetti CC; Winston EN; Lowe JA
Psychopharmacology (Berl); 1996 Apr; 124(4):315-22. PubMed ID: 8739546
[TBL] [Abstract][Full Text] [Related]
18. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.
Navarro M; Hernández E; Muñoz RM; del Arco I; Villanúa MA; Carrera MR; Rodríguez de Fonseca F
Neuroreport; 1997 Jan; 8(2):491-6. PubMed ID: 9080435
[TBL] [Abstract][Full Text] [Related]
19. Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats.
Norwood CS; Cornish JL; Mallet PE; McGregor IS
Eur J Pharmacol; 2003 Mar; 465(1-2):105-14. PubMed ID: 12650839
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
